DocMorris Logo
CH0042615283
A0Q6J0
ROSE.SW

DocMorris

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • DocMorris raises forecast after 260% rally and improves operating result

    The DocMorris share rose by around 260% over twelve months, driven by a markedly improved operating performance. At its capital markets day the company raised its revenue target to about 15% growth, supported by a strong Rx business (over 90% growth in prescription drugs in October) and improved margins. Adjusted EBITDA is expected to be at worst -10m CHF; a small positive was already achieved in the third quarter, and a free-cash-flow break-even is expected for 2027. Investors should note the strong rally and the earlier 200m CHF capital increase. » Mere på deraktionaer.de


  • DocMorris raises outlook after strong sales and prescription growth

    DocMorris increased sales in the third quarter by 21% to CHF 343m and reached CHF 971m in the first nine months (+14%). The prescription drug business grew in Q3 by 78% to CHF 108m, active customers rose by 1.5m to 13.1m. For 2026 the company now expects sales growth of 12–15% (in local currency) and lowers the expected EBITDA loss to below CHF 10m. The share price jumped about 8% and hit a 52-week high. » Mere på deraktionaer.de


  • Apothekerkammer seizes €110,000 from DocMorris following court rulings

    The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands against DocMorris for over €110,000 after the company was said to have breached final German judgments on advertising and discounts. German pharmacists had previously applied for administrative fines and achieved their enforcement in the Netherlands. DocMorris called the measure an enforcement of administrative fines, intends to appeal, and sees no impact on its operations or financial stability. » Mere på heise.de


  • Pharmacy chamber seizes €110,000 from DocMorris after breach of German judgments

    The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands for €110,000 after DocMorris was said to have violated final German judgments on advertising and discounts. DocMorris described the action as enforcement of administrative fines, announced it would appeal, and stressed that it has no impact on operations or financial stability. The case is part of the years-long dispute between the online provider based in the Netherlands and German brick-and-mortar pharmacies over competitive conditions and cross-border trade. » Mere på finanzen.net


  • DocMorris in the Netherlands seized over unpaid fines

    A court in Limburg ruled the seizure of accounts belonging to mail-order pharmacy DocMorris lawful after the Apothekerkammer Nordrhein applied for enforcement over unpaid, final administrative fines from Germany. The fines stem from prohibited price advertising, for which Stuttgart imposed several penalties (including €50,000, €60,000 and €100,000); the chamber says unpaid sums run into the millions. DocMorris can appeal within four weeks; the company did not comment on the proceedings. DocMorris is based in Heerlen and generated about €327.2m in revenue on the German market in Q1 2026 (+11.1%). » Mere på t-online.de

I 2016 har DocMorris allerede udloddet 0,46 € i udbytte. Den seneste udlodning fandt sted i juni 2016.

Virksomhedstal

I det seneste kvartal havde DocMorris en omsætning på 649,14 mio. € og et nettoresultat på -57,53 mio. €

(EUR) juni 2026
YoY
Omsætning 649,14 mio. -
Bruttofortjeneste 59,51 mio. -
Nettoresultat -57,53 mio. -
EBITDA -21,69 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
1,01 mia. €
Antal aktier
50,49 mio.
Højeste/laveste i 52 uger
21,19 € - 4,25 €
Udbytte Nej
Beta
1,86
P/E (PE Ratio)
-11,72
PEG (PEG Ratio)
-0,12
K/I (PB Ratio)
2,53
P/S (PS Ratio)
0,79

Virksomhedsprofil

Zur Rose Group AG driver et e-handelsapotek og en grossistvirksomhed for medicinske og farmaceutiske produkter under mærkerne Zur Rose og DocMorris i Tyskland, Schweiz og resten af Europa. Selskabet tilbyder produkter inden for forbrugersundhed, skønhed og personlig pleje. Selskabet leverer også ydelser inden for medicinhåndtering. Det driver fysiske apoteksbutikker. Selskabet sælger sine produkter direkte til læger, online postordreapoteker og privatpersoner. Selskabet var tidligere kendt som Zur Rose AG og skiftede navn til Zur Rose Group AG i maj 2015. Zur Rose Group AG blev grundlagt i 1993 og har hovedkontor i Frauenfeld, Schweiz.

Navn
DocMorris
CEO
Walter Hess
Hjemsted Frauenfeld, th
Schweiz
Websted
Sektor
Sundhed
Branche
Sundhedsudbydere og -tjenester
Børsnotering
06.07.2017
Medarbejdere 1.454

Tickersymboler

Børs Symbol
SIX
ROSE.SW
Düsseldorf
ZRE.DU
Frankfurt
ZRE.F
London
0RRB.L
München
ZRE.MU
Pnk
ZRSEF
London Stock Exchange
0RRB.L
Nse
IITL.NS
Australian Securities Exchange Ltd
SRX.AX
Bse
NILA.BO
Toronto Stock Exchange
EVGN.V
🍪

Parqet  bruger cookies. Læs mere